Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

Completed · Phase 2

Conditions studied: Hodgkin's Lymphoma

In brief

The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field radiation therapy. The hypothesis being studied is that this treatment will result in more than 80% of patients being alive and free of disease three years after starting treatment.

Key facts

Study ID

NCT00352027

Run by

St. Jude Children's Research Hospital

People needed

81

Starts

2006-07-20

Expected to finish

2022-11-15

Last updated by the study team

2023-09-22

Who can join

Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is less than or equal to 21 years of age
• Patient has a confirmed diagnosis of previously untreated Hodgkin lymphoma
• Has Ann Arbor stage IB, IIIA, or IA/IIA with extranodal extension, multiple nodal involvement (3 or more sites), or bulky mediastinal adenopathy.

You may not qualify if…

• Patients with favorable risk features
• Patients with unfavorable risk features
• Patients who have received prior therapy for Hodgkin lymphoma.

Where it is running

• Stanford University Medical Center — Palo Alto, California, United States
• Rady Children's Hospital San Diego — San Diego, California, United States
• Maine Children's Medical Center — Portland, Maine, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• St. Jude Children's Research Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.